Trulance (plecanatide) and Linzess (linaclotide) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat two types of constipation in adults: ...

Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 ...

Beyond LINZESS, Ironwood is advancing its pipeline with apraglutide, a next-generation long-acting synthetic GLP-2 analog being developed for short bowel syndrome with intestinal failure (SBS-IF). The ...

Linzess is a prescription medication for adults that treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The typical dosage of Linzess for IBS-C is 290 ...

Shares of Ironwood Pharmaceuticals IRWD were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026.

As with all medications, the cost of Linzess can vary. Factors that may affect the price you’ll pay include: your treatment plan your insurance coverage the pharmacy you use whether Linzess has a ...

Linzess may interact with anticholinergic drugs, such as oxybutynin (Ditropan XL), and antidiarrheal drugs, such as loperamide (Imodium). Taking these drugs with Linzess can make Linzess less ...

Backs FY25 adjusted EBITDA view greater than $135M. “Throughout 2025, we made significant progress in maximizing LINZESS ...

Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...

Sees FY26 adjusted EBITDA greater than $300M. “In 2026, we remain focused on our core priorities of maximizing LINZESS, ...